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ABSTRACT
Formation of multiple-protein macromolecular complexes at specialized
subcellular microdomains increases the specificity and efficiency of signaling in cells. In
this study, we demonstrated that phosphodiesterase type 3A (PDE3A) is physically and
functionally coupled to cystic fibrosis transmembrane conductance regulator (CFTR).
PDE3A inhibition increases cyclic adenosine 3′, 5′-monophosphate (cAMP) levels in a
compartmentalized manner at the plasma membrane, which potentiates CFTR channel
function and further clusters PDE3A and CFTR into microdomains. Actin skeleton
disruption reduces PDE3A-CFTR interaction and segregates PDE3A from its interacting
partners, thus compromising the integrity of the macromolecular complex. Consequently,
PDE3A inhibition no longer activates CFTR channel function in a compartmentalized
manner. Physiologically, formation of the CFTR-PDE3A-containing macromolecular
complexes was investigated using pig trachea submucosal gland secretion model. PDE3A
inhibition augments CFTR-dependent submucosal gland secretion and actin skeleton
disruption decreases secretion. These findings are important in understanding the
regulation of CFTR function by phosphodiesterases.
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CHAPTER 1: INTRODUCTION
Phosphodiesterases
Cyclic nucleotides and signaling
Cyclic adenosine-3′,5′-monophosphate (cAMP) and cyclic guanosine-3′,5′monophosphate (cGMP) are important secondary messengers in the cells. Their levels
have to be maintained precisely to regulate a variety of signaling cascades and cellular
processes such as metabolism, cell proliferation and differentiation, secretion, vascular
and airway smooth muscle relaxation and production of inflammatory mediators
(Thompson et al., 2007; Zaccolo, 2006). cAMP effects are through activation of a limited
number of effectors including cAMP-dependent protein kinase A (PKA), GTP-exchange
protein EPACs (exchange proteins activated by cAMP) and via cAMP-gated ion channel
(Halpin, 2008; Thompson et al., 2007). There is accumulating evidence for subcellular
compartmentalization of cAMP, permitting control of cAMP-dependent signal
transduction both spatially and temporally (Cooper, 2005; Halpin, 2008; Li et al., 2007).
Cyclic nucleotide phosphodiesterases
Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of the 3′,5′phosphodiester bond of cyclic nucleotides and thus play pivotal roles in regulating
intracellular concentrations and effects of secondary messengers cAMP and cGMP
(Beavo, 1995; Degerman et al., 1997). PDEs have been reported to interact with
regulatory proteins, scaffolding proteins and other signaling molecules to form
macromolecular complexes which increase specificity and efficiency in cAMP signaling
(Conti & Beavo, 2007). Eleven families of mammalian PDEs (PDE1-11) have been
reported. Most of the families have more than one member. PDE3 family has two
isoforms, PDE3A and PDE3B. PDE3s have distinctive characteristics which distinguish
them from other PDEs, e.g., an insert of 44 amino acids in the catalytic domain and six
hydrophobic putative transmembrane domains at the N-terminus. The structural
organization of PDE3A and PDE3B protein is identical. However, the two isoforms
exhibit tissue-specific expression and distinct cellular distributions (Conti & Beavo,
2007; Degerman et al., 1997; Meacci et al., 1992). PDE3s have high affinities for both
cAMP and cGMP (Km between 0.1-0.8µM) with Vmax for cAMP much higher than for
cGMP (Beavo, 1995; Conti et al., 1995; Degerman et al., 1997; Manganiello et al., 1995).
PDE3 is also called cGMP-inhibited PDE because of its inhibition by cGMP (Beavo,
1995; Conti et al., 1995; Manganiello et al., 1995). PDE3A has been shown to be
phosphorylated and activated by PKA, PKB and PKC in smooth muscle, oocytes and
platelets respectively (Han et al., 2006; Hunter et al., 2009; Murthy et al., 2002).
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Phosphodiesterase 3
PDE3A is the major isoform expressed in the heart, lung, and platelets where it
regulates physiological processes such as contraction of heart, relaxation of bronchial
smooth muscle, and platelet aggregation (Shakur et al., 2001). A pictorial representation
of PDE3A protein structure is shown in Fig. 1-1. PDE3B is highly expressed in
hepatocytes, adipocytes and beta cells and has been identified as a potential target for the
treatment of obesity and diabetes (Thompson et al., 2007). Specific PDE3 inhibitors,
presumably by inhibiting PDE3A, have been reported to enhance myocardial contractility
and induce vascular and airway smooth muscle relaxation and have been used to treat
heart failure and intermittent claudication (Halpin, 2008; Liu et al., 2001; Shin et al.,
2007). PDE inhibitors have also been shown to activate CFTR function in airway and
colonic epithelial cells (Kelley et al., 1995; Liu et al., 2005).
Cystic Fibrosis Transmembrane Conductance Regulator
CFTR in fluid homeostasis and regulation
CFTR is a cAMP-regulated chloride channel localized primarily at the apical
surfaces of epithelial cells lining airway, gut, exocrine glands, etc., where it is responsible
for transepithelial salt and water transport (Anderson et al., 1991; Bear et al., 1992;
Riordan et al., 1989). CFTR function is also critical in maintaining fluid homeostasis,
airway fluid clearance, and tracheal mucosal secretion in healthy and disease phenotypes
(Riordan, 2008; Wine & Joo, 2004). CFTR is regulated by the activities of adenylyl
cyclase (ACs) and PDEs through cAMP (Liu et al., 2005). A growing number of studies
suggest that CFTR interacts directly or indirectly with other transporters, ion channels,
scaffolding proteins, protein kinase, and cytoskeletal elements to form macromolecular
complexes (Li et al., 2005; Li & Naren, 2005; Naren et al., 2003; Yoo et al., 2004).
CFTR and mutations
The CFTR gene encodes a 1480 amino acid chloride channel protein with twelve
putative transmembrane domains (TMDs), two nucleotide binding domains (NBDs) and a
regulatory (R) domain (Riordan, 2005). A pictorial representation of CFTR protein is
shown in Fig. 1-2. Mutations in CFTR gene cause the expression of abnormal or nonfunctional chloride channel in most cases thereby causing the disease cystic fibrosis (CF).
Cystic fibrosis is a lethal autosomal recessive disorder usually associated with lung
disease, pancreatic insufficiency, and elevated sweat chloride levels (Quinton, 1986;
Rowntree & Harris, 2003). Although there are more than 1500 mutations described for
the CFTR gene, mutations in CF patients can be divided into six classes (Amaral &
Kunzelmann, 2007; Benharouga et al., 2001; Haardt et al., 1999; Rowntree & Harris,
2003; Zielenski & Tsui, 1995; Zielenski, 2000). The class I mutations constitute
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Figure 1-1. Pictorial representation of PDE3A
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Figure 1-2. Pictorial representation of CFTR showing transmembrane domains,
nucleotide binding (NBDs) domains, and regulatory (R) domain
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nonsense, splice and frame shift mutants that encode truncated forms of CFTR. The class
II mutations are mostly processing mutants that get trapped in the endoplasmic reticulum
(ER). The class III are regulation mutants and class IV are permeation mutants with
partial loss of function. The class V mutations show reduced mRNA stability. The class
VI mutations include C-terminal truncated CFTR which forms unstable mature protein
with several fold faster degradation rate than WT-CFTR.
Actin cytoskeleton and CFTR
The role of actin filaments in regulating the function and organization of ion
channels has been long established (Cantiello et al., 1991; Cantiello et al., 1993;
Cantiello, 1996). Actin cytoskeleton disruption has been shown to affect both CFTR
currents and the diffusion of the protein at the membrane (Cantiello, 2001; Ganeshan et
al., 2007; Haggie et al., 2006). Actin depolymerizing reagent latrunculin B was shown to
cause changes in CFTR dynamics (Haggie et al., 2006). Also, evidence for a direct
interaction between purified CFTR and actin has been provided by reconstituting CFTR
in lipid bilayer (Chasan et al., 2002). Given the evidence, it is logical to predict that actin
cytoskeleton plays an important role in maintaining the integrity of CFTR protein-protein
interactions as well.
Protein-protein Interactions and Compartmentalized cAMP Signaling
CFTR protein-protein interactions
The physical and functional coupling of multiple proteins involved in a complex
in compartmentalized domains is logical to achieve specific local signaling responses.
The role of macromolecular complex formation in compartmentalized signaling has been
elucidated for CFTR (Li & Naren, 2005; Li et al., 2007). The predominant adrenergic
receptor isoform in the airway epithelia is β2-adrenergic receptor (Abraham et al., 2003).
In airway epithelial cells, it has been shown that β2AR agonists activate CFTR function
(Li & Naren, 2005). Also CFTR was shown to form macromolecular complexes with
receptors and scaffolding proteins (LPA2, β2AR, NHERFs) to form a spatially, and
temporally, regulated localized cAMP signaling complex (Li et al., 2005; Li et al., 2007;
Naren et al., 2003). The role of PKA in regulating the function of CFTR in these
signaling complexes has been proved as well (Naren et al., 2003). Earlier, syntaxin 1A
and SNAP-23 were shown to bind CFTR and downregulate its activity (Naren et al.,
1997; Naren et al., 1998; Peters et al., 1999). Several PDZ proteins were shown to bind
CFTR which include NHERF1, NHERF2, CAP70, CAL and IKEPP (Cheng et al., 2002;
Hall et al., 1998; Short et al., 1998; Sun et al., 2000; Wang et al., 2000). Recently, it has
been shown that CFTR couples to MRP4 via CAP70 scaffolding protein to form a
temporally and spatially isolated microdomain for cAMP regulation of CFTR function
(Li et al., 2007). Such protein-protein interactions have been shown to play key roles in
pathophysiology as well. Altering CFTR function via its coupling to MRP4 or LPA2 has
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been shown to inhibit secretory diarrhea in mice in vivo (Li et al., 2005; Li et al., 2007).
A schematic of plausible CFTR macromolecular complex is shown in Fig. 1-3.
PDE protein-protein interactions
Phosphodiesterases such as PDE1, PDE3, PDE4, PDE6, PDE7 & PDE8 have
been shown to form higher order complexes and to be involved in protein-protein
interactions that regulate their function (Conti & Beavo, 2007). Interactions like CaM
with PDE1 and Xap2 with PDE4A5 are a few examples to implicate the importance of
protein-protein interactions in regulation of PDE activity (Bolger et al., 2003; Florio et
al., 1996). Shank 2 has been shown to interact with PDE4D and bring it physically close
to CFTR (Lee et al., 2007). PDEs have also been shown to interact with scaffolding
proteins like AKAPs bringing protein kinases into the macromolecular complex (DodgeKafka et al., 2006). For example, mAKAP and AKAP 450 have been shown to bind
PDE4D3 and form a complex, which can be tightly regulated by PKA in micro-domains
(Dodge et al., 2001; Tasken et al., 2001). PKA in this complex has been shown to
increase protein-protein interactions of PDE in the complex, and alter cAMP levels
locally by activating PDE. PDE4 has also been shown to interact with arrestin and this
interaction has been suggested to play an important role in receptor signaling (Perry et al.,
2002). PDE3 interaction with 14-3-3 and PDE 8 interaction with IκB are examples of
other PDE protein-protein interactions (Onuma et al., 2002; Wu & Wang, 2004). The
importance of these macromolecular complexes at a physiological level has been shown
in PDE4D null mice, in which, the dysfunction of the complex has been implicated to
play a role in progression of cardiac failure and arrhythmias seen under stress in these
mice (Lehnart et al., 2005). The existence of PDEs as dimers or oligomers in the cell has
also been reported for several isoforms (Conti & Beavo, 2007). There is a speculation
that loss of oligomerization leads to loss of catalytic activity, also, a change in affinity of
catalytic domain to certain inhibitors has been observed (Conti & Beavo, 2007; Richter &
Conti, 2004).
CFTR and Tracheal Submucosal Gland Secretion
Submucosal gland structure and function
Submucosal glands in the trachea secrete several substances including mucins,
anti-microbial substances and fluid which primarily form the mucus as a protective line
of defense. These glands contain ducts and secretory tubules (Meyrick et al., 1969). The
secretory tubules contain serosal and mucosal cells. A pictorial representation of
submucosal gland structure is shown in Fig. 1-4. Mucous cells secrete mucins and serous
cells secrete fluid and anti-microbial substances thereby providing a medium of
protection (Basbaum et al., 1990; Meyrick & Reid, 1970). CFTR protein expression is
found predominantly in the serosal cells of the submucosal glands and also in the apical
plasma membrane of ciliated cells (Engelhardt et al., 1992; Jacquot et al., 1993). CFTR is
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Figure 1-3. CFTR macromolecular complex. Modified from source: Naren, A.P., Cobb,
B., Li, C., Roy, K., Nelson, D., Heda, G.D., Liao, J., Kirk, K.L., Sorscher, E.J., Hanrahan,
J. & Clancy, J.P. (2003). A macromolecular complex of beta 2 adrenergic receptor,
CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA. Proc
Natl Acad Sci U S A. 100, 342-346. Copyright © (2003) National Academy of Sciences,
U. S. A.
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Figure 1-4. Submucosal gland structure. Modified from source: Ballard, S.T. &
Spadafora, D. (2007). Fluid secretion by submucosal glands of the tracheobronchial
airways. Respir Physiol Neurobiol. 159, 271-277. Copyright © (2007) Elsevier.
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believed to play pivotal role in fluid secretion and transport by actively transporting
chloride leading to sodium transport and thus driving osmotic water transport (Matthay et
al., 2002; Matthay et al., 2005). The early evidence for defect in chloride transport in
cystic fibrosis came from studies done in sweat ducts of CF patients (Quinton, 1983).
Several studies later confirmed that chloride, bicarbonate and liquid transport by
submucosal glands were important for lung function and the dysfunction of this transport
causes CF lung pathophysiology (Inglis et al., 1998; Trout et al., 1998). Submucosal
gland secretion in pig has been reported to be at least in part CFTR-dependent and this
dependence has also been reported in human and mouse tracheal submucosal gland
secretion (Choi et al., 2007; Ianowski et al., 2008). CF submucosal glands showed no
response to VIP and forskolin when compared to healthy non-CF submucosal glands
implicating an important role of CFTR in tracheal submucosal gland secretion (Wine &
Joo, 2004). Also, early studies suggested that CF submucosal glands secrete thick and
viscous mucus which obstruct the glands and impair mucociliary clearance thereby
promoting bacterial infections (Ballard & Spadafora, 2007; Zuelzer & Newton, 1949).
More recent studies using fluorescence recovery after photobleaching (FRAP) showed
that the CF gland secretion was more viscous and abnormal (Salinas et al., 2005).
Airway gland secretion in disease
Diseases like chronic obstructive pulmonary disease (COPD), asthma and cystic
fibrosis involve mucus hypersecretion, enlargement of submucosal glands, mucus plugs
leading to obstruction, and tracheobronchial submucosal gland hypertrophy (Barnes,
1996; Fahy et al., 1992; Finkbeiner, 1999; Samet & Cheng, 1994). Although the
characteristics of mucus plugs differ in asthma and COPD, they are inherent features of
both these diseases (Dunnill et al., 1969; Rogers, 2003). Obstruction of airway with thick
mucus and impaired mucus clearance is a major problem in airway diseases like asthma
(Rogers, 2004). Owing to the central role of CFTR in serosal fluid secretion and overall
fluid transport in healthy lung phenotype, it becomes mandatory to restore CFTR
function in disease phenotype. Methods or substances that increase CFTR function may
substantially help in restoring at least part of lung function by correcting fluid secretion
and transport.
Hypothesis and Specific Aims
The unifying hypotheses of my study is that phosphodiesterase 3A (PDE3A)
exists as a higher order complex, its interaction with cystic fibrosis transmembrane
conductance regulator (CFTR; a PKA activated chloride channel) is regulated by cAMP,
and that inhibition of PDE3A augments CFTR function.
The three specific aims of my study were to answer the questions:
•

Does PDE3A inhibition increase CFTR function, can PDE3A and CFTR interact,
and does PKA regulate the interaction at the plasma membrane?
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•
•

Can cAMP dynamics be monitored at the plasma membrane, and does PDE3A
inhibition increase cAMP at the plasma membrane?
Can we disrupt PDE3A-CFTR interaction, and does this alter CFTR function?
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CHAPTER 2: CLONING AND PURIFICATION OF PDE3A
Materials and Methods
Cloning of PDE3A into pcDNA3.1(-)-CFP and pcDNA3.1(-)-YFP vectors
A human full length PDE3A cDNA clone was obtained from Open Biosystems
(Huntsville, AL) in pCR4-TOPO vector. PDE3A was PCR amplified using Xho I and
KpnI forward and reverse primers. The primers used are:
PDE3A-XhoI-Forward:
AGTCCTCGAGATGGCAGTGCCCGGCGACGCTGCACGA
PDE3A-KpnI-Reverse:
ATGCGGTACCTCACTGGTCTGGCTTTTGGGTTGGTAT
The amplified PCR product was cleaned using the Qiagen kit and eluted in 20 µL
DNA grade water. The PCR cleaned sample was run on a 1% agarose gel. The product
was gene cleaned using Qiagen’s (Valencia, CA) QIAEX II kit. The cleaned product was
ligated into pcDNA3.1 (-)-CFP and pcDNA3.1 (-)-YFP which had been restriction
digested with XhoI and KpnI using Takara (Madison, WI) DNA ligation kit ver. 1, and
the ligated product was transformed into DH5α cells. Six clones were picked for culture
overnight; minipreps were done using Qiagen miniprep kit and the DNA was sent for
sequencing to Molecular Resource Center (MRC, UTHSC). The sequence was confirmed
to be pcDNA3.1 (-)-CFP-PDE3A and pcDNA3.1 (-)-YFP-PDE3A.
Ligation-independent cloning (LIC) of PDE3A into pTriEx-4 and pET-41 vectors
Human full length PDE3A and regulatory (R), catalytic, N-terminal and Cterminal domains were PCR-amplified. The PCR products were cleaned using Qiagen
PCR purification kit and eluted in 20 µL DNA grade water. The PCR-cleaned DNA was
further used for ligation independent cloning (LIC) using Ek/LIC cloning kit from
Novagen (EMD, Gibbstown, NJ). Primers used for LIC cloning were:
PDE3A-full-length-LIC Forward:
GACGACGACAAGATGGCAGTGCCCGGCGACGCTGCACGA
PDE3A-full-length-LIC Reverse:
GAGGAGAAGCCCGGTTCACTGGTCTGGCTTTTGGGTTGGTAT
PDE3A (N-tail) 1-61 amino acid
Forward: PDE3A-full-length-LIC Forward
Reverse: GAGGAGAAGCCCGGTCTAAAGTTTCCGAGAGCTCCGGAGCGGCTG
PDE3A (R-domain) 255-750 amino acid
Forward: GACGACGACAAGATGGTGGAACAAATCTTGCCGCAGTCCGCG
Reverse: GAGGAGAAGCCCGGTCTAAGGAATATCCCTATATCCAATCTCCAA
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PDE3A (Catalytic domain) 751-1035 amino acid
Forward: GACGACGACAAGATGTATCATAACAGAATCCATGCCACTGAT
Reverse: GAGGAGAAGCCCGGTCTAATCTCCTGACTCATCGCTGTCTTCCAC
PDE3A (C-tail) 1036-1141 amino acid
Forward: GACGACGACAAGATGACTGATGACCCAGAAGAAGAGGAGGAA
Reverse: PDE3A-full-length-LIC Reverse
14.6 µL of PCR-purified DNA was taken into a clean centrifuge tube and 2 µL
each of 10X T4 DNA polymerase buffer and 25 mM deoxy-adenosine triphosphate
(dATP) were added. 1 µL of 100 mM dithiothreitol (DTT) and 0.4 µL of T4 DNA
polymerase were added to make a 20 µL total volume reaction mix. The reaction was
started by adding the enzyme and stirring gently and incubated at 22°C for 30 min. The
reaction was then stopped by inactivating the enzyme with 75°C incubation for 20 min.
This T4 DNA polymerase-treated insert can be annealed into any Ek/LIC vectors.
pTriEx-4 and pET-41 vectors were used to ligate this insert. For the ligation reaction, 1
µL Ek/LIC vector pTriEx-4 or pET-41 and 2 µL of T4 DNA polymerase-treated insert
were used and incubated at 22°C for 5 min. Then, 1 µL of 25 mM EDTA was added for 5
min at 22°C. The ligated product was transformed into Novablue cells. Three clones were
picked for each vector, plasmid DNA was isolated and sent for sequencing. The
sequences were confirmed to be PDE3A. pTriEx-4 has a HIS-S tag whereas pET41 has a
GST-HIS-S tag, and thus pTriEx-4-PDE3A with HIS-S tag and pET41-PDE3A with
GST-HIS-S tags were generated. pTriEx-4 was chosen for eukaryotic expression and
pET-41 for bacterial protein purification.
Generation of Flag and HA tagged PDE3A
To generate full length PDE3A with Flag or HA tag on the putative first outer
loop, PDE3A was sub-cloned into pcDNA3 using XhoI and KpnI restriction enzymes.
After generating pcDNA3-PDE3A construct, site-directed mutagenesis was used to insert
a Flag or HA tag between amino acid position 104 and 105. Quickchange site-directed
mutagenesis kit (Stratagene, La Jolla, CA) was used and mutagenic primers were
designed based on the kit guidelines. The primers (forward and reverse for Flag or HA
insertion) were as follows:
PDE3A-104-Flag-Forward
GAGGAGGAAGCAGCCGACTATAAAGACGACGACGACAAACCGGGAGCAGA
AGGG
PDE3A-104-Flag-Reverse
CCCTTCTGCTCCCGGTTTGTCGTCGTCGTCTTTATAGTCGGCTGCTTCCTCCTC
PDE3A-104-HA-Forward
GAGGAGGAAGCAGCCTATCCATATGACGTCCCAGACTATGCCCCGGGAGCAG
AAGGG
PDE3A-104-HA-Reverse
CCCTTCTGCTCCCGGGGCATAGTCTGGGACGTCATATGGATAGGCTGCTTCCT
CCTC
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For the mutant strand synthesis reaction, 30 ng of template DNA and 125 ng each
of forward and reverse primers were used in a 50 µL reaction for PCR. The amplified
PCR product was treated with DpnI and transformed into XL-gold ultracompetent cells.
Six clones were cultured, plasmid DNA isolated, and sent for sequencing. The sequences
confirmed the presence of a Flag or HA tag at amino acid position 104 in full length
PDE3A. A schematic for generation of PDE3A constructs is shown in Fig. 2-1.
Generation of HEK-293 and Calu-3 stable cell lines expressing Flag- or HA-tagged
PDE3A
HEK-293 or Calu-3 cells were transfected with pcDNA3-Flag-PDE3A or
pcDNA3-HA-PDE3A and selected with G418 (0.4 mg/ml) to generate stable cell lines
expressing Flag or HA tagged PDE3A. HEK-293 or Calu-3 cells were plated on 60 mm
dishes at a density of approximately 106 cells per dish. The next day, cells at about 80%
confluence were transfected with pcDNA3-Flag-PDE3A or pcDNA3-HA-PDE3A or
control using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). About 5 µl of
Lipofectamine was used for 2 µg of DNA. After 48 h, selection was started by replacing
the media with media containing 0.4 mg/ml G418. Media was replaced everyday with
G418 media for 2-3 weeks till colonies of stable cells survived and all other cells died.
These colonies were picked by trypsinization and maintained in G418 media.
Purification of Flag-, HA-, or HIS-S-tagged PDE3A
HEK-293 cells were plated on 10 cm dishes, transfected with pcDNA3-FlagPDE3A, pcDNA3-HA-PDE3A or pTriEx-4-PDE3A (full length or domain specific
constructs) and grown for 48 h. The cells were then washed with PBS twice and lysed
with PBS containing 0.2% Triton-X-100 and protease inhibitor cocktail (aprotinin,
leupeptin, pepstatin and phenylmethylsulphonyl fluoride (PMSF)). The cell lysate was
mixed on a shaker for 10 min at 4°C and centrifuged for 10 min at 13,000 rpm. The
supernatant containing total protein was immunoprecipitated using α-Flag, α-HA beads
or S-protein agarose beads overnight. The beads with bound protein were washed and the
protein was eluted with 100 mM glycine (pH 2.2) and quickly neutralized with 150 mM
tris (pH 8.8). The eluted protein was subjected to SDS-PAGE on 4-15% gel (Bio-Rad,
Hercules, CA) and transferred to PVDF membrane and either visualized with Gel Code
Blue or immunoblotted with α-Flag-HRP, α-HA-HRP or α-S-HRP antibody. A
coomassie gel with purified PDE3A is shown in Fig. 2-2.
To test if we could purify large amount of fusion protein, recombinant GST-HisS-PDE3A-N-terminal protein was induced in E.coli using IPTG (0.2 mM). The fusion
protein was purified using affinity chromatography (glutathione beads). The GST-fusion
protein was eluted using 10 mM glutathione in TBS (pH 7.4) and was further purified
using size exclusion chromatography. A chromatogram and coomassie gel for PDE3A-Nterminus is shown in Fig. 2-3.
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Figure 2-1. Generation of PDE3A constructs with tags
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Figure 2-2. Purification of full-length PDE3A
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Figure 2-3. Purification of PDE3A-N-terminus
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Assay for enzymatic activity of purified full length PDE3A
We used a radioactive 3H-cAMP phosphodiesterase assay for measuring PDE3A
enzymatic activity (Thompson et al., 1979). In the first step, PDE converts the radioactive
cAMP into AMP. In the second step, nucleosidase from snake venom further converts
AMP to adenosine. Ion exchange chromatography (AG® 1-X 8 resin; Bio-Rad, Hercules,
CA) was used to separate cAMP and AMP from adenosine. Radioactive adenosine was
measured in a scintillation counter.
Results
In this part of the study, we demonstrated the cloning and purification of PDE3A
with various tags. The fluorescent CFP and YFP tags are critical to study protein-protein
interactions in live cells using imaging techniques like FRET. Flag, HA, GST, HIS and S
tags are crucial for biochemical studies like co-immunoprecipitation and protein
purification. Generation of pcDNA3-PDE3A with various epitope tags was important for
making stable cell lines. Stable cell lines expressing significant amount of PDE3A is the
first and most essential requirement to carry out any biochemical studies. This is
mandatory not only to purify significant amounts of protein but also to identify
interacting partners. HEK-293 cells were chosen due to the ease of transfection, their
human origin and response to various agonists. Also, we have HEK-293 cells stably
expressing CFTR, which are known to respond to adenosine and β-adrenergic receptor
agonists. We also found endogenous expression of PDE3A in HEK-293 cells by
immunoblotting. This made the cell line more appealing and useful for our studies on
PDE3A-CFTR interaction. Calu-3 (lung serosal epithelial cell line) on the other hand
endogenously expresses both CFTR and PDE3A and also forms transepithelial membrane
resistant monolayers when grown on transwell supports and thus is an ideal choice for
our CFTR functional studies. Thus, we made stables of Flag-PDE3A and HA-PDE3A in
both HEK-293 and Calu-3 cell lines. We purified full length PDE3A (~ 130 kDa band)
from both the cell lines. To verify that the full-length protein was indeed PDE3A, we sent
the purified protein out for mass spectrometry and the results identified the protein as
PDE3A. Further, we purified recombinant GST-HIS-S-PDE3A domains (N-terminal, Cterminal, regulatory and catalytic) from E.coli. To confirm that the purified full-length
PDE3A was functional, we used radioactive cAMP phosphodiesterase assay and found
the protein had enzymatic activity when present on beads but loses activity soon after
elution. We also confirmed that the insertion of Flag or HA tag on the first outer loop of
PDE3A does not effect the activity of the protein.
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CHAPTER 3: PDE3A AND CFTR; PHYSICAL AND FUNCTIONAL COUPLING
VIA COMPARTMENTALIZED cAMP GENERATION
Materials and Methods
Reagents
Trequinsin, cilostazol and rolipram were purchased from Biomol (Plymouth
Meeting, PA). Forskolin was obtained from Tocris (Ellisville, MO). Isoproterenol was
purchased from Calbiochem (EMD, Gibbstown, NJ). DSP was obtained from Pierce
(Thermo Fisher, Rockford, IL). Adenosine, IBMX, cpt-cAMP, latrunculin B, carbachol,
and indomethacin were purchased from Sigma-Aldrich (St. Louis, MO).
Cell culture and transfections
HEK293 cells were cultured in DMEM-F12 media containing 10% serum and 1%
penicillin/streptomycin and maintained in a 5% CO2 incubator at 37oC. Calu-3 cell line
was purchased from ATCC (Manassas, VA) and cultured in MEM media containing 15%
serum, 1% penicillin/streptomycin, 1 mM sodium pyruvate and 1X non-essential amino
acids. Lipofectamine 2000 was used to express plasmids containing CFTR or PDE3A in
both HEK293 and Calu-3 cell lines according to the manufacturer’s instructions. Stable
cell lines were generated by selection using 0.4 mg/ml G418 (geneticin).
Short circuit current (ISC) measurements
Polarized lung serosal cells (Calu-3) monolayers were grown on Costar Transwell
permeable supports (filter area 0.33cm2) until the monolayer reached a resistance of
~1500 ohms and the transwell was mounted in an Ussing chamber. Short circuit currents
were measured as described previously (Li et al., 2005). Epithelia were bathed in
Ringer’s solution (mM) (Basolateral: 140 NaCl, 5 KCl, 0.36 K2HPO4, 0.44 KH2PO4, 1.3
CaCl2, 0.5 MgCl2, 4.2 NaHCO3, 10 HEPES, 10 glucose, pH 7.2, [Cl-] = 149), and low ClRinger’s solution (mM) (Apical: 133.3 Na-gluconate, 5 K-gluconate, 2.5 NaCl, 0.36
K2HPO4, 0.44 KH2PO4, 5.7 CaCl2, 0.5 MgCl2, 4.2 NaHCO3, 10 HEPES, 10 mannitol, pH
7.2, [Cl-] = 14.8) at 37°C, and saturated with 95% O2 and 5% CO2. The monolayers were
bathed in a low chloride Ringer’s solution on the apical side and normal Ringer’s solution
on the basolateral side. A 2 mV pulse was applied every 1 min throughout the experiment
to check for the integrity of the epithelia. PDE3-specific inhibitor cilostazol (10-100 µM)
was added to apical and basolateral sides. Forskolin (20 µM) was added to both sides for
maximal response. CFTRinh-172 (20 µM) was added to the apical side. For ISC
measurements with actin cytoskeleton disruption of the cells, latrunculin B (1 µM) was
added to both apical and basolateral sides after pre-treating the cells with latrunculin B (1
µM) for 30 min.
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Membrane preparation and immunoblotting
For detecting PDE3A expression and localization in cells using Western blotting,
crude membrane and cytosolic fractions were isolated. In order to prepare crude
membrane and cytosol, HEK-293 parental cells, Calu-3 cells or Calu-3 cells transfected
with HA-PDE3A were grown on 10 cm dishes. The dishes were washed with PBS and
scraped in PBS and the cells pelleted at 600 g for 5 min at 4°C. The pellet was then
resuspended by incubation with hypotonic lysis buffer (10 mM HEPES, 1 mM EDTA,
protease inhibitor cocktail, pH 7.2) for 10 min before lysis by 10 strokes in Dounce
homogenizer, followed by 15 strokes in the presence of equal volume of sucrose buffer
(500 mM sucrose, 1 mM EDTA, 10 mM HEPES, pH 7.2). The lysate was spun at 6000 g
for 20 min at 4°C to obtain post-mitochondrial supernatant. Crude membrane was
collected by centrifuging the supernatant at 100,000 g for 45 min at 4°C. The pellet was
resuspended in isotonic buffer (250 mM sucrose, 1 mM EDTA, 10 mM HEPES, pH 7.2)
to collect crude membrane and supernatant was used for cytosolic fraction. The protein
was mixed with Laemmli sample buffer (5x; containing 2.5% β-mercaptoethanol),
denatured, subjected to SDS-PAGE on 4-15% gel and transferred to PVDF membrane.
PDE3A mAb from Novus Biologicals (Littleton, CO) was used for immunoblotting.
Coimmunoprecipitation and immunoblotting
Cells transfected with Flag-CFTR and HA-PDE3A or only HA-PDE3A were
lysed using lysis buffer (1x PBS, containing 0.2% Triton-X-100 and protease inhibitors
phenylmethylsulfonyl fluoride 1 mM, pepstatin-A 1 µg/ml, leupeptin 1 µg/ml, aprotinin 1
µg/ml). The lysate was centrifuged at 16,000 g for 10 min at 4 ºC and the clear
supernatant was subjected to immunoprecipitation using α-Flag beads (Sigma-Aldrich,
St.Louis, MO). The immunoprecipitated beads were washed three times with lysis buffer
and the protein was eluted from the beads using Laemmli sample buffer (5x; containing
2.5% β-mercaptoethanol). The eluates were denatured and subjected to SDS-PAGE on 415% gel. The protein was transferred to PVDF membrane. PDE3A mAb from Novus
Biologicals (Littleton, CO) was used for immunoblotting.
Cross-linking the complex and immunoblotting
Thiol-cleavable, amine-reactive, homobifunctional cross-linker dithiobis
succinimidyl propionate (DSP, 1 mM) was used to cross-link protein complex in HEK293 cells grown on 10 cm dishes expressing both Flag-CFTR and HA-PDE3A. HEK-293
cells expressing only Flag-CFTR were used as control. The cells were pre-treated with 1
µM latrunculin B for 30 min at 37°C and then cross-linked with 1 mM DSP for 5 min at
37°C. The reaction was quenched by lysing the cells with ice-cold RIPA buffer (140 mM
NaCl, 1% Nonidet P40, 0.5% Na-deoxycholate, 0.1% Na-dodecyl sulphate and 50 mM
Tris-HCl, pH 8.0) containing protease inhibitor cocktail. The supernatant was spun at
20,000 rpm for 10 min. After taking 100 µL of total protein for input, the rest of the
protein was immunoprecipitated by adding α-HA beads overnight. The beads were
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washed twice with RIPA buffer and the cross-linked complex was eluted with 100 mM
glycine (pH 2.2) and quickly neutralized with 150 mM Tris (pH 8.8). For cleaving the
disulphide bond of DSP and separating the proteins, 2.5% β-mercaptoethanol was added
to the sample Laemmli buffer. The eluted proteins were mixed with Laemmli sample
buffer (5x; containing 2.5% β-mercaptoethanol), denatured, subjected to SDS-PAGE,
transferred to PVDF membrane and immunoblotted using α-M3A7-CFTR antibody from
Millipore (Billerica, MA).
Surface biotinylation and immunoblotting
Cells expressing HA-PDE3A were surface biotinylated with EZ-Link Sulfo-NHSLC-Biotin from Pierce (Rockford, IL) for 1 h at 4°C, lysed, and immunoprecipitated
using α-HA agarose beads (Sigma-Aldrich, St.Louis, MO). The biotinylated purified HAPDE3A was pulled down using streptavidin beads (Pierce, Rockford, IL) for 1 h at room
temperature. The beads were spun down to collect unbound fraction, and the beads
contained the bound fraction. The samples were mixed with Laemmli sample buffer (5x;
containing 2.5% β-mercaptoethanol), denatured, subjected to SDS-PAGE on 4-15% gel,
transferred to PVDF membrane and immunoblotted with α-PDE3A mAb from Novus
Biologicals (Littleton, CO).
FRET microscopy and data analysis
For ratiometric FRET, HEK 293 cells expressing CFP-EPAC-YFP were grown on
glass-bottom dishes (MatTek, Ashland, MA), washed twice with Hank’s balanced salt
solution (HBSS) and mounted on an inverted Olympus wide-field microscope (IX51, UPlan Fluorite 60x 1.25 NA oil-immersion objective) for FRET imaging. The stage was
maintained at 37°C constantly and the cells were maintained in the dark in HBSS. After
establishing the baseline, PDE inhibitors were added as indicated. Ratiometric FRET
imaging was performed as described previously (Li et al., 2007). Time-lapse images were
obtained with 1x1 binning, 100-300 ms exposure time and 1 min intervals. Images were
acquired using an EM CCD camera (Hamamatsu) mounted on an Olympus IX51. The
light source used was 300W xenon lamp with a neutral density filter. A JP4 CFP/YFP
filter set was used for image capture (Chroma, Brattleboro, VT) which includes a 430/25
nm excitation filter, a double dichroic beam splitter and two emission filters (470/30 nm
for CFP and 535/30 nm for FRET emission) alternated by filter-change controller
Lambda 10-3 (Sutter instruments, Novato, CA). Slidebook 4.2 software was used for data
analysis. Following background subtraction, multiple regions of interest (10-20) were
selected (3-5 cells) for data analysis using ratio module. The emission ratio (CFP/FRET)
was obtained from CFP and FRET emission of background subtracted cells.
For direct sensitized emission FRET, HEK 293 cells were transiently transfected
with pCDNA3-CFP-PDE3A or pCDNA3-YFP-CFTR or both using Lipofectamine 2000.
Single transfected cells were used to acquire CFP or YFP only images for bleed through
calculations. Double transfectants were used for data collection using CFP/YFP filter
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sets. The cells were split at low density at 20-40% confluence into a cover slip bottom
dish (MatTek; Ashland, MA), washed twice with warm HBSS and 2 ml of HBSS was
added. Cells were imaged in a dark room at 37°C. After acquiring images without PKA
agonists as 0 time point images, PKA activating cocktail (Forskolin 10 µM, IBMX 100
µM, cpt-cAMP 200 µM) was added and images were acquired at 2, 4, 6, 8 and 10 min
intervals. Corrected FRET was calculated on a pixel-by-pixel basis for the entire image
by using equation: FRETc = FRET - (0.5 × CFP) - (0.06 × YFP), where FRET, CFP, and
YFP correspond to background-subtracted images of cells co-expressing CFP-PDE3A
and YFP-CFTR acquired through the FRET, CFP, and YFP channels, respectively
(Galperin & Sorkin, 2003). The factors 0.5 and 0.06 are the fractions of bleed-through of
CFP and YFP fluorescence, respectively, through the FRET filter channel. The corrected
FRET (FRETc) was normalized with donor CFP intensity (FRETc/CFP), yielding the
normalized corrected FRET (N-FRETc), and the intensity of N-FRETc images was
presented in monochrome mode, stretched between the low and high renormalization
values, according to a intensity to color mapped lookup table with black indicating low
values and white indicating high values. All calculations were performed using the
Channel Math and FRET modules of the SlideBook 4.2 software (Intelligent Imaging
Innovations; Denver, CO).
Single particle tracking
Calu-3 cells stably expressing HA-PDE3A were grown on 35 mm glass bottom
dishes (MatTek, Ashland, MA). Cells were washed twice with phosphate buffered saline
containing 6 mM glucose and 1 mM sodium pyruvate (PBS/Glu/NaPyr) and blocked with
PBS/Glu/NaPyr containing 4% bovine serum albumin (BSA) for 10 min. Cells were then
incubated with biotin α-HA antibody (1 µg/ml, Sigma-Aldrich, St. Louis, MO) for 15
min, washed five times, followed a second incubation with streptavidin-conjugated Qdot655 (0.1 nM, Invitrogen, Carlsbad, CA) for 2 min, washed 8 times, and immediately
mounted on an Olympus inverted microscope (IX51), and the images were captured with
Hamamatsu EM-CCD camera at 1-3 frames per second (fps) for 1-3 min with 50 ms
exposure time, 100x oil-immersion objective (NA 1.40), xenon (300W lamp) light
source, and SlideBook 4.2 software. Qdot 655-A BrightLine® high brightness and
contrast single band filter set (Semrock, Rochester, NY) was used for collecting data.
Single particle tracking was done using particle tracking module of SlideBook 4.2
software, which generates trajectories and also calculates MSD. Diffusion coefficient (D)
was calculated by linear squares fitting using points 1-5 on the MSD curve. 5-10 cells
were used for plotting histograms of diffusion coefficient. To monitor changes in
diffusion with cytoskeletal disruption, cells were pre-treated with latrunculin B (1 µM, 30
min) and latrunculin B was also added to the buffer during the course of the experiment.

21

Submucosal gland secretion
Submucosal gland secretion was monitored and analyzed as described by Wine’s
laboratory (Joo et al., 2001). Freshly collected pig trachea was placed in cold KrebsRinger bicarbonate buffer (120 mM NaCl, 25 mM NaHCO3, 3.3 mM KH2PO4, 0.8 mM
K2HPO4, 1.2 mM MgCl2, 1.2 mM CaCl2, 10 mM D-glucose and 1 µM indomethacin).
The submucosal layer was carefully dissected from the cartilage and a 1 cm piece was
mounted in a chamber mucosal side up. The mucosal side was wiped and quickly airdried with 95% O2 and 5% CO2 gas. A thin layer of water-saturated mineral oil was
applied to the mucosal side. The tissue was constantly maintained at 37°C and gassed
with 95% O2 and 5% CO2 after mounting. To establish a baseline, Krebs-Ringer
bicarbonate buffer was added to the serosal side. PDE3 inhibitor cilostazol, CFTR
inhibitor 172 and latrunculin B (10 µM) were added to the serosal side after monitoring
basal secretion. Carbachol was added at the end of the experiment to check for the
viability of submucosal glands. Images were collected at 1 min time intervals with a
digital camera (Motic Images 2.0 ML software, National Optical, San Antonio, TX)
attached to a stereoscopic microscope (National Optical, San Antonio, TX) and analyzed
using ImageJ software (NIH, Bethesda, MD). A 1 mm x 1 mm grid was placed on the
tissue in the last image for area measurements. Volume was calculated from area using
the formula v = Πr3 and rate was calculated as slope of volume vs. time plot by fitting at
least four points using linear regression.
Surface labeling assay
Cells expressing Flag or HA-PDE3A grown on 35 mm dishes were fixed with
3.7% formaldehyde for 10 min, blocked with 1% BSA for 30 min, and treated with αFlag or HA-HRP (0.2 µg/ml) for 90 min. HRP substrate 1-step Ultra TMB (Pierce,
Rockford, IL) was added to the dishes for about 10-20 min, and the reaction was stopped
by adding equal amount of 2 M H2SO4 and the absorbance was read at 450 nm. To detect
any altered surface expression with PKA phosphorylation, cells were pre-treated with
forskolin (20 µM) for 10 min, fixed, surface labeled and then assayed. To detect the
effects of latrunculin B on PDE3A surface expression levels, Calu-3 cells expressing HAPDE3A were pre-treated with latrunculin B (1 µM) for 30 min and then proceeded for
surface labeling as described above.
Iodide efflux assay
CFTR mediated halide efflux was measured using iodide efflux assay. HEK-293
cells expressing wild type CFTR were grown on 60 mm dishes, and iodide efflux was
assayed as described. Briefly, cells were loaded for 60 min at room temperature with
loading buffer (136 mM NaI, 137 mM NaCl, 4.5 mM KH2PO4, 1 mM CaCl2, 1 mM
MgCl2, 10 mM glucose, 5 mM HEPES, pH 7.2). Extracellular NaI was washed away
thoroughly (5 times) with efflux buffer (136 mM NaNO3 replacing 136 mM NaI in the
loading buffer) and cells were equilibrated for 1 min in a final 1 ml aliquot. The first four
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aliquots were used to establish a stable base line in efflux buffer alone. Agonist (1 µM
adenosine with or without 100 µM cilostazol or 5 µM isoproterenol with or without 20
µM trequinsin) was added to the efflux buffer and samples were collected every 1 min for
6 min in the continued presence of agonists (i.e., the efflux buffer used for subsequent
replacements also contained agonists at the same concentration). The iodide
concentration of each aliquot was determined using an iodide-sensitive electrode
(Thermo Scientific, Waltham, MA) and converted to iodide content (nanomoles/min).
HEK 293 parental cells in the presence of agonist forskolin were used as a negative
control.
Immunofluorescence
Calu-3 cells on glass-bottom dishes were directly used after fixing with 3.7%
formaldehyde or paraffin embedded pig trachea was processed for immunostaining.
Paraffin embedded pig trachea was sectioned. The slides with sections were treated with
protease to retrieve the antigen. The cells on dishes and antigen retrieved sections were
blocked with PBS with 4% BSA and 0.2% Triton-X-100, inside a humidifying chamber
for 2 h. The slides or dishes were treated with rabbit polyclonal α-PDE3A from Santa
Cruz Biotechnology (Santa Cruz, CA) at 1:50 dilution overnight. Normal rabbit IgG was
used for negative control. The slides were treated for 1 h with secondary antibody αrabbit AlexaFluor 488 (Molecular probes, Invitrogen, Eugene, OR) at 1:500 dilution and
1:1000 dilution of propidium iodide. Images were taken on a Carl-Zeiss (Thornwood,
NY) confocal microscope. For co-localization experiments, rabbit polyclonal α-PDE3A
and mouse monoclonal α-CFTR primary antibodies were used and AlexaFuor 488 and
568 secondary antibodies were used. Normal rabbit and mouse IgG were used for
negative control. Calu-3 cells were fixed for 30 min at -20°C using acetone-methanol and
further fixed with 3.7% formaldehyde.
AlphaScreenTM for PDE3A-CFTR interaction
We used AlphaScreen™ (Amplified Luminescent Proximity Homogeneous
Assay) to study CFTR-PDE3A interaction. Purified full-length Flag tagged CFTR and
biotinylated HA-PDE3A were used and 2103 EnVision multilabel plate reader was used
to measure the fluorescence between acceptor and donor beads. AlphaScreen™ FLAG™
(M2) detection kit was used to detect the interaction between purified full-length biotin(HA)-PDE3A and Flag-(M2)-wt-CFTR. In brief, starting from 100 nM final
concentration, biotin-(HA)-PDE3A was serially diluted (in 1/2 log dilution series) in
assay buffer [1x PBS, 0.1% BSA, 0.05% Tween 20 (v/v), pH 7.2] containing Flag-wtCFTR (100 nM final concentration). The resulting solutions were incubated at room
temperature for 30 min. Each sample solution (15 µl) was transferred to a white opaque
384-well microplate (OptiPlateTM-384, PerkinElmer, MA) in triplicates and into which
anti-FLAG (M2) acceptor beads (5 µl, 20 µg/ml final concentration) were added and
incubated for 30 min at room temperature. Streptavidin donor beads (5 µL, 20 µg/ml final
concentration) were then added and incubated for 2 h at room temperature. The plate was

23

read on an EnVisionTM 2103 Multilabel Reader (PerkinElmer, MA) or FLUOstarOmega plate reader with AlphaScreen™ capability (BMG labtech, Durham, NC).
Cell-attached single-channel recording
Single-channel recordings were obtained from Calu-3 cells as described
previously (Li et al., 2007). The pipette solution contained either forskolin or cilostazol
(10-20 µM) to activate CFTR channels. Both bath and pipette solution contained (in mM)
140 N-methyl-D-glucamine, 140 HCl, 2 CaCl2, 2 MgCl2, 10 HEPES, pH 7.4. Single
channel currents were recorded at a test potential of +80 mV (reference to the cell
interior) delivered from the recording electrode, and were filtered at 100 Hz and sampled
at 2 kHz.
Statistical analyses
Statistical analyses were done using Student’s t-test (2-tailed) or ANOVA (singlefactor), and p < 0.01 or p < 0.05 was considered significant. All the results are
represented as mean + SEM with n being the number of experiments.
Results
PDE3A inhibition augments CFTR function by generation of compartmentalized cAMP
Submucosal glands secretion plays important roles in maintaining airway and
lung health. It is usually stimulated by agonists that elevate cAMP or Ca2+ level and has
been reported to be at least in part CFTR-dependent (Choi et al., 2007; Ianowski et al.,
2008). To explore the physiological relevance of functional coupling between CFTR and
PDE3A, we used pig tracheal submucosal gland secretion model. Pig is considered a
closer model to human cystic fibrosis (CF), and a CF pig model is available for studying
CFTR function (Rogers et al., 2008). After established basal secretion, a specific PDE3
inhibitor, cilostazol (100 µM), was added to the serosal side to inhibit PDE3A. Cilostazol
has been approved for treatment of intermittent claudication since 1999 in the USA and
for treatment of peripheral artery occlusive disease (PADO) in Japan since 1988
(Thompson et al., 2007). As shown in Fig. 3-1, upon PDE3A inhibition, we observed a 3fold increase in mean mucosal secretion rate (from 0.5 nl/min/gland basal secretion rate
to 1.5 nl/min/gland). This increased secretion was inhibited by treatment of the trachea
with a specific CFTR channel inhibitor, CFTRinh-172 (50 µM), suggesting that the
increased secretion is CFTR-dependent. Carbachol, an agonist which stimulate the glands
secretion by elevating Ca2+ level, was added at the end of the experiments to check for
the viability of submucosal glands (Fig. 3-1).

24

Figure 3-1. CFTR dependent submucosal gland secretion increases with PDE3A
inhibition
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The expression and localization of PDE3A in pig trachea was studied by
immunohistochemical analysis using a PDE3A-specific antibody and α-rabbit AlexaFluor
488 as the secondary antibody. We also investigated the localization of PDE3A in Calu3 cells, a widely used model for submucosal gland serous cells (Ianowski et al., 2008).
Non-immune rabbit IgG was used as a negative control in these studies. As can be seen in
Fig. 3-2, PDE3A is primarily localized at the plasma membrane of epithelial cells of pig
trachea and at the plasma membrane of Calu-3 cells. It is to be noted that CFTR is also
expressed at the plasma membrane of Calu-3 cells (Li et al., 2004; Li et al., 2005; Naren
et al., 2003). We also used immunofluorescence to detect co-localization between
PDE3A and CFTR endogenously. Calu-3 cells showed co-localization of PDE3A and
CFTR (Fig. 3-2).
To investigate if the functional coupling of PDE3A and CFTR can be observed in
live cells, we used two CFTR Cl- channel function assays. The first one was to measure
CFTR-dependent short circuit current (ISC) in polarized Calu-3 cells mounted in an
Ussing chamber (Li et al., 2007). Consistent with the observation of Drumm’s group
(Kelley et al., 1995), PDE3A inhibition increased CFTR Cl- channel function. In the
presence of PDE3 inhibitors trequinsin (1-20 µM) or cilostazol (10-100 µM), we
observed a dose-dependent increase in CFTR-mediated currents which was inhibited by
CFTRinh-172 (20 µM) (Fig. 3-3). Forskolin (20 µM), a adenylyl cyclase stimulator
which elicits a global increase of cAMP and maximally stimulates CFTR function (Li et
al., 2005; Li et al., 2007), was used as positive control for these studies. It is to be noted
that inhibition of PDE3A induced smaller magnitude of ISC response compared to that
stimulated by forskolin (20 µM). In the case of using cilostazol, the ISC could be further
increased to a maximal level by using forskolin (20 µM) suggesting that inhibition of
PDE3A generates localized cAMP rather than global cAMP.
The second CFTR functional assay we used was to measure the iodide efflux
from HEK293 cells overexpressing Flag-wt-CFTR. Adenosine or isoproterenol were
used to activate CFTR channel function in these studies and HEK293 parental cells
stimulated by forskolin were used as negative control. As can be seen in Fig. 3-4,
inhibition of PDE3A increased CFTR-mediated iodide efflux. In the presence of
cilostazol (100 µM), the iodide efflux increased > 50% when a low dose of adenosine (1
µM) was used. Similarly, by using trequinsin (20 µM), the iodide efflux increased > 50%
when a low dose of isoproterenol (5 µM) was used. Adenosine is a cAMP-elevating
ligand which has been reported to stimulate CFTR channel function in a
compartmentalized manner at the apical cell membranes when being used at low (< 20
µM) concentrations (Huang et al., 2001; Li et al., 2007). Isoproterenol is a β adrenergic
receptor (β-AR) agonist which acts via activation of β-AR and AC to induce cAMP.
The expression and localization of PDE3A in HEK293 cells and Calu-3 cells was
studied by Western blotting. Calu-3 cells transfected with HA-PDE3A were used as
positive control (Fig. 3-5). The results show that PDE3A is expressed in the membrane of
these cells.
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Figure 3-2. Immunofluorescence and co-localization of PDE3A
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Figure 3-3. Ussing chamber data shows PDE3 inhibition augments CFTR function
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Figure 3-4. Iodide efflux assay shows HEK-293-Flag-CFTR cells show increased CFTR
function with PDE3 inhibition
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Figure 3-5. PDE3A is expressed in the membrane of HEK-293 and Calu-3 cells
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To further characterize the localization of cAMP upon PDE3A inhibition and to
investigate the possible mechanism through which CFTR functionally couples to PDE3A,
a FRET-based cAMP sensor, CFP-EPAC-YFP, was transfected into HEK293 cells and
then subjected to ratiometric fluorescence resonance energy transfer (FRET)
measurements. This highly sensitive, unimolecular fluorescent cAMP indicator allows to
monitor cAMP dynamics in intact cells with very high temporal and spatial resolution (Li
et al., 2007; Ponsioen et al., 2004). As can be seen from Fig. 3-6, upon PDE3A inhibition
by using cilostazol, cAMP levels (represented by CFP/FRET emission ratio) increased in
a dose-dependent manner. More importantly, the increase of cAMP levels occurs mainly
at the edge area of the cells, suggesting a highly compartmentalized cAMP accumulation
at the plasma membrane. Interestingly, addition of a PDE4 inhibitor, rolipram (10µM),
induced a global increase in cAMP levels (indicated by the uniform increase of the
emission ratio in the entire cytoplasm) which is similar to the effect seen with forskolin
stimulation (20µM; Fig. 3-7). It seems reasonable to propose that in these cells PDE3A is
probably involved in compartmentalized cAMP signaling whereas PDE4 regulates global
cAMP levels. Taken together, our data showed that PDE3A is functionally coupled to
CFTR. Inhibition of PDE3A augments CFTR function by generation of highly
compartmentalized cAMP.
PDE3A interacts with CFTR in a PKA-dependent manner
Given the evidence of functional coupling, we continued to investigate whether a
physical coupling between PDE3A and CFTR existed. Towards this, we co-transfected
HEK293 cells with CFP-PDE3A and YFP-CFTR and measured the direct sensitized
emission FRET in live cells. A schematic diagram of FRET assay is shown in Fig. 3-8.
As shown in Fig. 3-9, the two proteins interacted at the plasma membrane as indicated by
the FRET signals. More importantly, this interaction increased by almost 70%
(normalized FRET) upon treatment with a PKA-activating cocktail (forskolin 10 µM,
IBMX 100 µM, and cpt-cAMP 200 µM), suggesting that the interaction between CFTR
and PDE3A is PKA-dependent. Phosphorylation increases the binding between PDE3A
and CFTR. To confirm that CFP and YFP do not show FRET by themselves, we
transfected cells with CFP and YFP only and observed that there was no significant
FRET between the fluorophores (Fig. 3-10).
Coimmunoprecipitation and immunoblotting were also used to detect the
interaction between PDE3A and CFTR. HEK293 cells were co-transfected with HAPDE3A and Flag-CFTR, immunoprecipitated using α-Flag beads and immunoblotted for
PDE3A. Cells transfected with HA-PDE3A were used as negative control. For all the
protein interaction studies, we generated PDE3A constructs with either Flag or HA tag on
the first outer loop at position 104 and CFTR with Flag tag at position 901 on the fourth
outer loop (Fig. 3-11). As shown in Fig. 3-12, HA-PDE3A can be coimmunoprecipited
with Flag-CFTR, suggesting interaction exists between these two proteins which
corroborate the FRET data.
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Figure 3-6. Compartmentalized cAMP is generated with PDE3 inhibition
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Figure 3-7. PDE3 inhibition generates local cAMP whereas forskolin generates global
cAMP
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Figure 3-8. Schematic diagram for FRET
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Figure 3-9. FRET reveals interaction between CFTR and PDE3A in live cells
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Figure 3-10. CFP and YFP by themselves do not show FRET
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Figure 3-11. Generation of HA and Flag tagged PDE3A and CFTR
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Figure 3-12. Co-immunoprecipitation shows interaction between PDE3A and CFTR
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To investigate if the interaction between PDE3A and CFTR is direct, we purified
full-length Flag-CFTR and full-length biotinylated HA-PDE3A. Amplified luminescent
proximity homogeneous assay (AlphaScreenTM) FLAG (M2) detection kit was used to
study the interaction between these two purified proteins. A schematic diagram for
alphascreen assay is shown in Fig. 3-13. The AlphaScreenTM assay is a highly sensitive
method which can be used to detect direct interactions between interacting partners at
femtomolar concentrations (Ullman et al., 1996). For these studies, we kept Flag-CFTR
concentration constant (100 nM final concentration) and used increasing concentrations
of biotinylated HA-PDE3A (10 pM to 100 nM). As can be seen from Fig. 3-14, HAPDE3A interacts directly with Flag-CFTR at nanomolar concentrations and in a dosedependent manner.
To test whether the increased interaction between PDE3A and CFTR by PKA
phosphorylation is due to the altered surface expression levels of PDE3A, we used
surface labeling assay to study the expression of Flag- or HA-PDE3A at the plasma
membrane of Calu-3 cells. A schematic diagram for surface labeling assay is shown in
Fig. 3-15. Calu-3 cells endogenously expressing PDE3A were used as control. The
formaldehyde-fixed cells were labeled with α-Flag-HRP or α-HA-HRP and incubated
with HRP substrate 1-step Ultra TMB. The reaction was stopped by addition of 2 M
H2SO4 and absorbance was read at 450 nm. As shown in Fig. 3-16, Flag- or HA-PDE3A
is expressed at the plasma membrane of Calu-3 cells and the tags are indeed on the outer
loop of the protein.
To further verify the surface expression of PDE3A, we surface labeled HEK293
cells expressing HA-PDE3A with a cell-impermeable biotinylating reagent Sulfo-NHSLC-biotin at 4°C, lysed the cells and immunoprecipitated using α-HA agarose beads. The
purified biotinylated HA-PDE3A was pulled down using streptavidin beads and the
bound and unbound fractions were immunoblotted for PDE3A. HEK293 parental cells
were used as negative control. We found that more than 90% of PDE3A is present at the
plasma membrane of transfected HEK293 cells (Fig. 3-17). Next, we investigated the
effects of PKA-phosphorylation on the surface expression levels of Flag-PDE3A. Calu-3
cells transfected with Flag-PDE3A were pre-treated with PKA activating agonist
(forskolin, 20 µM) and then subjected to surface labeling as described above. The results
showed that PKA-phosphorylation does not increase PDE3A surface expression levels as
indicated by the unchanged absorbance between forskolin pre-treated cells and untreated
cells (Fig. 3-18).
Based on these results, we proposed that, PDE3A and CFTR are in close
proximity to each other at the plasma membrane of epithelial cells (e.g., Calu-3 cells).
Inhibition of PDE3A generates highly compartmentalized cAMP, which further clusters
PDE3A and CFTR into microdomains and augments CFTR channel function in a
compartmentalized manner.
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Figure 3-13. Schematic diagram for alphascreen assay
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Figure 3-14. AlphaScreen™ indicates direct interaction of purified CFTR and PDE3A
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Figure 3-15. Schematic diagram for surface labeling assay
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Figure 3-16. Flag and HA tagged PDE3A are expressed on the plasma membrane
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Figure 3-17. The majority of PDE3A is expressed on the membrane
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Figure 3-18. PKA phosphorylation does not alter surface expression of PDE3A
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Cytoskeleton disruption reduces the physical and functional interaction between PDE3A
and CFTR
All of the described data suggested the physical and functional coupling between
PDE3A and CFTR. The next question we asked was: can we dissociate the clusters of
PDE3A and CFTR at the plasma membrane and would this dissociation alter specifically
PDE3A-dependent CFTR Cl- channel function? Actin cytoskeleton has been shown to be
important for maintaining CFTR in highly restricted domains on the plasma membrane
(Jin et al., 2007). Actin filament organization has also been shown to play functional role
in the activation and regulation of CFTR Cl- channel function (Cantiello, 1996; Chasan et
al., 2002; Ganeshan et al., 2007). Therefore, we continued to investigate the effects of
cytoskeleton disruption on the physical and functional coupling between PDE3A and
CFTR to see if cytoskeleton plays an important role in the physical and functional
integrity of macromolecular complexes. Latrunculin B, a specific actin-disrupting reagent
which causes actin filament depolymerization, was used for these purposes.
We first investigated the effects of actin cytoskeleton disruption on HA-PDE3A
dynamics in live Calu-3 cells by using single particle tracking (SPT) method. A
schematic diagram of single particle tracking assay is shown in Fig. 3-19. SPT is a
powerful method to study the dynamics of individual proteins in the plasma membrane of
live cells (Chen et al., 2006). HA-PDE3A (HA tag on the first outer loop at position 104)
was labeled with biotin α-HA antibody and then conjugated to streptavidin-conjugated
Qdot-655 for monitoring lateral mobility on the plasma membrane. The mean diffusion
coefficient of PDE3A (0.0025 µm2/s) we observed in this study is similar to that reported
for CFTR (Bates et al., 2006; Jin et al., 2007), indicating the confined diffusion of
PDE3A. As shown in Fig. 3-20, when the cells were treated with latrunculin B (1 µM), a
significant increase in the mean squared displacement (MSD) and diffusion coefficient of
PDE3A was observed (mean diffusion coefficient: 0.0117 µm2/s; a 4.7-fold increase
compared to the untreated cells). It is reasonable to propose that actin cytoskeleton
disruption compromised the integrity of multiprotein complex and caused PDE3A to
move freely, thus uncoupling PDE3A from the CFTR-containing complex.
To further investigate if the physical interaction between PDE3A and CFTR was
reduced with cytoskeleton disruption, we co-transfected HEK293 cells with Flag-CFTR
and HA-PDE3A and cross-linked these two proteins in live cells using
dithiobissuccinimidyl propionate (DSP; 1 mM) with or without latrunculin B treatment.
The cells were then lysed in RIPA buffer (containing 1 M urea) to disrupt all interactions
except antigen-antibody interaction and the proteins were co-immunoprecipitated using
α-HA beads and immunoblotted for CFTR. HEK 293 cells expressing only Flag-CFTR
were used as negative control. DSP is a thiol-cleavable, amine-reactive homobifunctional
cross-linker which has been used to cross-link proteins of interest in live cells (Li et al.,
2004). The result showed that latrunculin B treatment led to a significant decrease in
PDE3A-CFTR interaction (Fig. 3-21).

46

Figure 3-19. Schematic diagram of single particle tracking assay

47

Figure 3-20. Single particle tracking of PDE3A with or without latrunculin B shows
different diffusion patterns
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Figure 3-21. Latrunculin B decreases physical interaction between CFTR and PDE3A
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We also tested the effects of actin disruption on functional coupling between
PDE3A and CFTR. To test our hypothesis in a physiologically relevant system, we used
latrunculin B in pig trachea submucosal gland secretion studies. As can be seen in
Fig. 3-22, when treated with latrunculin B, a significant decrease (> 90%) in cilostazolactivated and CFTR-dependent mean mucosal secretion was observed. The data are
consistent with the findings from the ISC studies. We observed that latrunculin B itself
can cause a small decrease of mean mucosal secretion rate. We ruled out the possibility
of altered surface expression of PDE3A on latrunculin B treatment by using surface
labeling assay which showed that the surface expression level of PDE3A is not
significantly changed (Fig. 3-23).
CFTR-dependent short-circuit currents were measured in polarized Calu-3 cells
mounted in an Ussing chamber. As shown in Fig. 3-24, ISC measurements in cells treated
with latrunculin B showed that the potentiating effects of PDE3A inhibition (cilostazol:
10-100 µM) on CFTR-dependent currents decreased by almost 65-80% compared to the
cells without latrunculin B treatment. However, it is to be noted that the maximallystimulated ISC by forskolin (by increasing global cAMP) remained unaffected by
latrunculin B treatment (Fig. 3-24).
Cell-attached single-channel recording in Calu-3 cells strongly supported our
hypothesis and shed more mechanistic insights into the physical and functional coupling
between PDE3A and CFTR and its actin cytoskeleton dependence. Cilostazol or forskolin
was applied in the pipette to active CFTR channel function. As shown in Fig. 3-25, there
was no significant change in single channel conductance for cells activated by either
cilostazol or forskolin with or without latrunculin B treatment. CFTR channel open
probability was significantly decreased in cilostazol activated currents when treated with
latrunculin B. However, forskolin activated currents were not altered with latrunculin B
treatment.
These data clearly indicated that PDE3A inhibition activated CFTR channel
function in a compartmentalized manner and the coupling between these two proteins
was actin cytoskeleton dependent. Cumulatively, our findings provided clear evidence
that, 1) PDE3A was physically, and functionally, coupled to CFTR at the plasma
membrane through compartmentalized cAMP; 2) inhibition of PDE3A generated high
levels of compartmentalized cAMP which further clustered the two proteins into
microdomains and potentiated CFTR Cl- channel function; 3) cytoskeleton disruption
decreased CFTR-PDE3A interaction, probably by scattering CFTR and PDE3A away
from each other and compromising the integrity of the macromolecular signaling
complexes, leading to the loss of compartmentalized cAMP signaling. Consequently,
inhibition of PDE3A no longer potentiated CFTR Cl- channel function in
compartmentalized fashion. A model for CFTR and PDE3A coupling via
compartmentalized cAMP generation is shown in Fig. 3-26.
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Figure 3-22. CFTR dependent tracheal submucosal gland secretion is not increased with
PDE3 inhibition when treated with latrunculin B
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Figure 3-23. Surface expression of PDE3A is not altered in the presence of latrunculin B
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Figure 3-24. Latrunculin treatment inhibits local increase of CFTR function by PDE3
inhibition whereas global increase by forskolin is not altered
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Figure 3-25. Latrunculin B treatment alters open probablility of CFTR with PDE3
inhibition whereas forskolin response is unaltered
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Figure 3-26. Model for PDE3A and CFTR coupling via compartmentalized cAMP
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CHAPTER 4: DISCUSSION
It is now well accepted that the formation of multiple-protein macromolecular
complexes at specialized subcellular microdomains increases the specificity and
efficiency of signaling in cells (Li & Naren, 2005; Li et al., 2007). The main goal of this
study was to investigate the physical and functional coupling between CFTR Cl- channel
and PDE3A and its physiological relevance in airway gland mucus secretion.
Physical and Functional Coupling between CFTR and PDE3A
In this study, we found that PDE3A is expressed at the plasma membrane of
epithelial cells of pig trachea, Calu-3 cells, and HEK293 cells. These data are supported
by results from immunohistochemical analysis, Western blotting and cell surface labeling
studies. We demonstrated that CFTR directly interacts with PDE3A in a PKA-dependent
manner by using FRET, cross-linking, co-immunoprecipitation and AlphaScreenTM
assay. We also observed the functional coupling between PDE3A and CFTR Cl- channel
function. Inhibition of PDE3A augmented CFTR Cl- channel function as seen in ISC and
iodide efflux measurements. Studies on cAMP localization and dynamics by using a
FRET-based cAMP sensor, CFP-EPAC-YFP, showed that, upon PDE3A inhibition,
cAMP was generated in highly compartmentalized fashion at the plasma membrane. All
these data indicated that CFTR and PDE3A form macromolecular complexes at the
plasma membrane through compartmentalized cAMP. This hypothesis was further
supported by the facts that actin cytoskeleton disruption decreased CFTR-PDE3A
interaction, probably by scattering CFTR and PDE3A away from each other and
compromising the integrity of the macromolecular complexes. Consequently, inhibition
of PDE3A no longer activated CFTR Cl- channel function in compartmentalized fashion
as evidenced by cell-attached single-channel recording studies, ISC measurements and pig
tracheal submucosal gland secretion studies in the presence of latrunculin B, an actin
skeleton disrupting reagent. Based on these results, we propose a model to depict the
mechanism through which the physical and functional coupling between PDE3A and
CFTR Cl- channel occurs.
Compartmentalized cAMP and PDE3A Signaling
One of the key features of cAMP/PKA signal transduction system has been
suggested to be the compartmentalization of its signaling enzymes and effectors that
generates localized cAMP and activates PKA at distinct subcellular locations (Zaccolo,
2006). PDEs have been shown to play vital roles in such compartmentalized signaling
processes. The emerging idea is that it is the compartmentalization of individual PDEs,
rather than total expression level, which is of vital importance in modulating localized
intracellular cAMP levels (Zaccolo, 2006). Kinase-anchoring proteins (AKAPs) have
been reported to play key roles in the assembly and organization of such
compartmentalized cAMP/PKA signaling. AKAPs anchor PKA and PDEs to specific
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intracellular locations in close vicinity to specific modulators and targets to achieve
signaling specificity and efficiency (Langeberg & Scott, 2005; McConnachie et al.,
2006). Tasken et al. reported that PDE4D3 and PKA form a signaling complex in the
centrosomal area which is coordinated by the centrosomal AKAP450 and regulates
accurate spatiotemporal cAMP signals (Tasken et al., 2001). Lee et al. demonstrated that
a PDZ-containing protein, Shank2, competes with NHERF1 for binding to CFTR.
Shank2 associates with PDE4D and tethers it to CFTR complex and thus attenuates
cAMP/PKA signals (Lee et al., 2007). Pozuelo et al. reported that PDE3A binds directly
to 14-3-3 proteins in a phosphorylation-dependent manner and PDE3A also binds to
plectin, a cytoskeletal linker protein (Pozuelo Rubio et al., 2005). More recently,
Puxeddu et al. demonstrated that PDE3A interacts with brefeldin A-inhibited guanine
nucleotide-exchange proteins (BIG1 and BIG2) in HeLa cell cytosol via
compartmentalized cAMP signaling with spatial and temporal specificity (Puxeddu et al.,
2009).
In this study, we report a previously unknown physical and functional coupling
between CFTR and PDE3A and propose that they form a signaling macromolecular
complex at the plasma membrane. Other signaling components such as specific G
protein-coupled receptors (GPCRs), G proteins (Gs), AC, PKA and anchoring proteins
(AKAPs) may also be present in the proposed macromolecular complexes which
synergistically regulate compartmentalized cAMP signaling and specificity of CFTR
activation.
Physiological Relevance of CFTR-PDE3A-containing Macromolecular Complexes in
Airway Gland Mucus Secretion
Regulation of CFTR channel function via its interaction with PDE3A is of
physiological and pathophysiological importance owing to: 1) CFTR is the primary
cAMP-activated Cl- channel on the apical membrane of airway epithelia, thus playing
critical roles in controlling the electrolyte/fluid balance and mucociliary clearance
process (Pilewski & Frizzell, 1999), 2) phosphodiesterase inhibition remains a viable area
of therapy for the treatment of airway diseases such as asthma and COPD (Fan Chung,
2006). Submucosal gland secretion has been reported to play important roles in
maintaining airway and lung health and CFTR has been shown to play important roles in
such process. This idea is supported by the observations that CF glands have altered
response to secretagogues compared with normal glands (Ianowski et al., 2008) and by
the fact that in CF patients the airway host defenses system are compromised, leading to
chronic secondary bacterial infections and inflammation in the lung and respiratory
failure (Pilewski & Frizzell, 1999; Sheppard & Welsh, 1999).
Drugs targeting PDEs are being considered for their cardiotonic, pulmonary
vasodilator, smooth muscle relaxant, antithrombotic, antiinflammtory, and antiasthmatic
properties (Conti & Beavo, 2007). Targeted inhibition of PDE4 has been pursued as a
way of reducing inflammation in patients with asthma or COPD, diseases characterized
by mucus-congested and inflamed airways (Barnette, 1999; Compton et al., 2001).
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Cilomilast and roflumilast, two second generation PDE4 inhibitors, have shown potential
benefit for treatment of asthma and COPD. However, clinical utility of PDE4 inhibitors
has been limited by adverse effects, including nausea, diarrhea, and vomiting (Fan
Chung, 2006; Halpin, 2008).
Although PDE3 inhibitors do not appear to have direct anti-inflammatory actions,
they have been shown to augment the anti-inflammatory actions of PDE4 inhibitors
(Giembycz et al., 1996; Schudt et al., 1995). Also, PDE3 inhibitors could act as
bronchodilators and may have synergistic effects with PDE4 inhibitors (Halpin, 2008).
Development of dual specificity inhibitors (such as dual PDE3-PDE4 inhibitors) may
provide more bronchodilator and bronchoprotective effect in addition to the beneficial
PDE4 effects (Giembycz, 2005).
PDE3 and PDE4 have been reported to be the major PDEs present in airway
epithelial cells (Torphy, 1998; Wright et al., 1998). Inhibition of PDE4 and/or PDE3 has
been demonstrated to activate CFTR Cl- channel function (Cobb et al., 2003; Kelley et
al., 1995; Liu et al., 2005). However, the mechanism through which the functional
coupling occurs remains unclear. In this study, we demonstrated that PDE3A is
physically and functionally coupled to CFTR and form macromolecular complexes
together with other signaling molecules. Inhibition of PDE3A augments CFTR Clchannel function by generation of highly compartmentalized cAMP. However, inhibition
of PDE4 using rolipram led to globally increased cAMP. These findings not only provide
insights into the important roles of PDE3A in compartmentalized cAMP signaling
processes, but may also have important implications in the therapeutic interventions of
diseases such as CF, asthma, and COPD: 1) targeting PDE3A and development of
isoform-specific PDE3A inhibitors (or dual specificity inhibitors) may open new avenue
in PDEs drug development, 2) inhibition of PDE3A has the beneficial effects of localized
potentiation of CFTR channel function (through compartmentalized signaling) and thus
submucosal gland secretion. These additional benefits would help to restore and maintain
airway and lung health.
In this study, we have identified that compartmentalized cAMP at the plasma
membrane is generated by inhibiting PDE3A, which is functionally and physically
coupled to the CFTR chloride channel and thus to tracheal mucosal secretion. We suggest
that PDE3A and CFTR are in close proximity to each other on the plasma membrane.
Inhibition of PDE3A lead to generation of compartmentalized cAMP at the plasma
membrane, which, in turn, lead to increased clustering of these two proteins and the
maintenance of a high degree of specificity. Actin cytoskeleton disruption altered PDE3A
dynamics and its physical and functional coupling with CFTR. Such regulation of CFTR
function via its interaction with PDE3A might be of physiological relevance owing to the
relevance of CFTR in fluid transport and homeostasis.
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